

Lifecycle Management considerations as it includes changes throughout the lifecycle of the product

Hasmukh B. Patel,, Ph.D. Division Director Division of Product Quality Assessment III Office of Pharmaceutical Assessment I OPQ/CDER

IPAC-RS Sustainability Roundtable March 14, 2024




Outline

- Lifecycle management of drug products
- Type of post-approval changes
- Enablers of post-approval changes
- Conclusion



Ensures medicines

OPQ Focus on Lifecycle Management



www.fda.gov

OPQ Focus on Lifecycle Management

OPQ's Holistic Approach

The product lifecycle can be divided into 4 phases based on the natural progress of drug product development.

Focus is given to the entire drug product line with an emphasis on knowledge sharing



nges?

Why Post-Approval CMC Changes?

- Continuous improvement
 - Product optimization
 - Incorporating a new technologies
 - Process improvement
- Regulatory Requirements/Commitments
- Product quality issues
- Business reasons
- Supply and demand



Typical Post-Approval CMC Changes

Drug substance

- New manufacturing site
- New supplier for regulatory starting materials
- Route/method of synthesis
- Manufacturing process
- In-process controls and/or drug substance specifications
- Retest period



Typical Post-Approval CMC Changes

Drug product

- New manufacturing site
- Manufacturing process and/equipment
- Formulation
- Container/closure system
- Device/ device material change in drug-device combination products
- Specifications
- Shelf-life
- Introduction of new strengths

Regulatory basis for Post-approval Changes

21 CFR 314.70

- § 314.70 Supplements and other changes to an approved application.
- The applicant must notify FDA about each change in each condition established in an approved application



Classification of CMC Changes

- Major changes (Prior Approval Supplements)
 - Cannot be implemented until approved
- Moderate changes (Changes Being Effected in 30 Days Supplements)
 - Can be implemented 30 days after submission at the applicants own risk
- Minor changes (changes being effected in 0 days supplement or Annual report
 - Can be implemented immediately upon receipt by FDA



Type of Supplements

- Efficacy supplement
 - New indication
 - Changes in the dosing regimen
 - Safety Changes (precautionary statements/Blackbox warning/new contraindications)
 - Addition of dosing information for special population
- Labeling supplements
 - Changes in the approved labeling, including prescribing information, immediate container and carton labels, medication guide, etc.
- CMC supplements
 - Changes in the drug substance and/or drug product manufacturing, analytical changes, site changes etc..



Enablers of Lifecycle Management

- Comparability protocols
- Post-approval change management protocol (PACMP) (ICH Q12)
- Emerging technology



• A *Comparability Protocol* is a comprehensive, prospectively written plan for assessing the effect of a proposed CMC post-approval change(s) on the identity, strength, quality, purity, and potency of a drug product or a biological product (i.e., product), as these factors may relate to the safety or effectiveness of the product (i.e., product quality).

Agency definition in draft guidance published April 2016



- An optional way to manage post-approval changes [21CFR314.70© and 21 CFR 601.12(e)
- Can be used to implement a CMC post-approval change
- Facilitates post-approval changes and drug product lifecycle management
- Useful for drug products with accelerated manufacturing development
- Reporting category for implementation of CP may be downgraded depending on the product and process knowledge, risk assessment, and the controls strategy.



- Can be submitted in the original applications (NDA, ANDA, and BLA) and in supplements
- Submitted post-approval, submission of a PAS is required.
- Can be submitted for one or more changes
- Can be submitted to cover an identical change(s) that affects multiple applications
- Can be for one-time change(s) or be used repeatedly for a specified change over the life cycle of a product



When submitting a comparability protocol, consider:

- Effective use of knowledge and understanding of the product and manufacturing process
- A robust control strategy
- Risk management
- An effective pharmaceutical quality system

ICH-Q12 – Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management

- Scope:
 - Applies to pharmaceutical products, including marketed chemical, biological and biotechnological products
- Objectives:
 - Best practices for management of post-approval CMC changes
 - Emphasis on risk-based approaches (compliments ICH Q8-Q11)
 - Facilitates regulatory flexibility

ICH-Q12 – Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management

ICHQ12 contains the following fundamental tools and enablers to support a harmonized lifecycle management:

- Established Conditions (EC)
- Product Lifecycle Management (PLCM)
- Post-Approval Change Management Protocols (PACMP)
- Pharmaceutical Quality Systems (PQS)

Established Conditions (ICH Q12)

- Elements in an application considered necessary to assure product quality
- Legally binding when submitted and approved in the application
- Can be submitted in the original application or post-approval
- If submitted post-approval, submission of a PAS is required.
- Established conditions should be justified.
- PLCM should list proposed established conditions and filing categories for making changes.
- Filing categories could be other than that required by existing regulations and/or guidances
- Any change to ECs necessitates a submission to the regulatory authority



Post-approval Change Management Protocol (PACMP)

- Also known as "comparability protocols"
- Post Approval Change Management Protocols (PACMPs): A regulatory tool that provides predictability and transparency in terms of the requirements and studies needed to implement a change
- An approved PACMP provides an agreement between the firm and the regulatory authority



Post-approval Change Management Protocol (PACMP)

- Outline future change(s) to be made
- Tests, studies, etc. to be conducted to verify acceptability of change
- Proposed reporting category; often reduced compared to existing guidance and regulation.



Emerging Technology

What is Emerging Technology?

- Technology with the potential to modernize the body of knowledge associated with pharmaceutical development to support more robust, predictable, and/or cost-effective processes or novel products and with which the FDA has limited review or inspection experiences, due to its relative novelty
- Innovative or novel product, manufacturing process, or analytical technology subject to quality assessment (including review and inspection)



Emerging Technology

- Emerging technologies for small molecules
 - Continuous manufacturing of drug substance
 - Continuous manufacturing of drug product
 - Model-based control strategy for continuous manufacturing
 - Continuous aseptic spray drying
 - 3D printing manufacturing
 - Ultra long-acting oral formulation
- Emerging technologies for biological molecules
 - Controlled ice nucleation for lyophilization processes
 - Advanced process control: predictive modeling for process monitoring; close loop bioreactor control; feed forward impurity control



Changes to Container Closure Systems Inhalation Drug Products

- Inhalation drug products
 - Metered dose inhalers (MDIs)
 - Dry powder inhalers (DPIs)
 - Nasal spray
 - Inhalation solutions and suspensions



Container Closure System for Drug Device Combination Products

- Inhalation drug products
 - Propellant-based inhalation and nasal aerosols
 - Metered dose inhalers (MDIs)
 - Dry Powder inhalers (DPIs)
 - Non-propellant-based inhalation products
 - Nasal spray
 - Inhalation solutions and suspensions

Suitability of Container Closure System

- Compatibility with the drug product formulation (leachables)
- Performance (dose delivered)



Changes Over the Lifecycle of Drug Product

- Change in the components of drug product container closure system
- Changes in the device components

FDA Factors Affecting Safety and Efficacy of Drug Products

- Materials used for fabrication of device and container closure systems
 - Leachables (safety and effectiveness)
 - Aerodynamic performance (delivered dose and aerodynamic particle size distribution (APSD) by surface properties of device part
 - Drug particle surface interactions (adhesion) affecting delivered dose and APSD
 - Biocompatibility



Meetings with FDA

- Types of meeting
 - Type A
 - Granted within 30 days
 - Type B
 - Granted within 60 days
 - Type C
 - Granted within 75 days



Relevant FDA Guidances

- Guidance for Industry: Changes to an Approved NDA or ANDA, 4/8/2004
- Guidance for Industry: Changes to an approved NDA or ANDA, Questions and Answers, 1/1/2001
- Guidance for Industry Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization Guidance for Industry, September 2017
- Guidance for Industry Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Guidance for Industry, MAY 2021
- Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products – Chemistry, Manufacturing and Controls Documentation, July 2002



Conclusion/Summary

- Application of ICH Q12 and emerging technologies enable enhancement of product quality and continual improvement of product manufacturing process and controls throughout the product lifecycle.
- Effective use of knowledge management and product and process understanding along with a robust control strategy, risk assessment, and pharmaceutical quality system are essential for regulatory flexibility throughout the drug product lifecycle management.



Thank You!